Norway Antifungal Drugs Market Size & Outlook, 2023-2030
Norway antifungal drugs market, 2018-2030 (US$M)
Related Markets
Norway antifungal drugs market highlights
- The Norway antifungal drugs market generated a revenue of USD 159.1 million in 2023 and is expected to reach USD 208.4 million by 2030.
- The Norway market is expected to grow at a CAGR of 3.9% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 159.1 million |
| Market revenue in 2030 | USD 208.4 million |
| Growth rate | 3.9% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Norway accounted for 1.0% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,215.7 million by 2030.
Azoles was the largest segment with a revenue share of 47.64% in 2023. Horizon Databook has segmented the Norway antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
Key players, such as Almirall, S.A. are offering late-stage pipeline products for fungal infections, such as onychomycosis. This includes products such as Efinaconazole. The company expects to launch this product in Norway in 2023 after its approval.
Such approvals and launches of novel products in the country are expected to propel its market. The Norwegian Medicines Agency (NoMA) is responsible for the approval of pharmaceutical products in the country.
It overall supervises the production, approval, and marketing of medicines. It also ensures the cost-effectiveness and usage of drugs in the country and further regulates the prices & trade conditions for pharmacies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway antifungal drugs market size, by drug class, 2018-2030 (US$M)
Norway Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
